Core Viewpoint - The company has successfully established a private equity investment fund, which has completed the necessary registration with the China Securities Investment Fund Industry Association [1] Group 1: Fund Establishment - The company participated in the investment to set up the Shanghai Chuangte Private Equity Investment Fund Partnership (Limited Partnership) [1] - The fund has obtained the Private Equity Fund Registration Certificate, with the registration code SAXM42 [1] - The fund manager is Shanghai Shangtou Venture Capital Co., Ltd., and the custodian is Huaxia Bank Co., Ltd. [1] Group 2: Future Actions - The company will continue to monitor the fund's subsequent developments and fulfill its information disclosure obligations in a timely manner [1]

Group 1 - The company has announced its participation in the establishment of the Shanghai Chuangte Private Investment Fund Partnership (Limited Partnership), which has completed its business registration [1] - The fund has a total scale of 56 million yuan, with an initial capital contribution of 10 million yuan [1] - As of the announcement date, the initial capital contribution has been completed, with the following contributions from partners: Shanghai Shengtou Venture Capital Co., Ltd. (GP, manager) 1 million yuan, Shanghai Bailian Guotai Junan Chuangling Private Fund Partnership (Limited Partnership) 6 million yuan, Shanghai First Pharmaceutical Co., Ltd. (LP) 1 million yuan, Shanghai Fengxian Biotechnology Park Development Co., Ltd. (LP) 1 million yuan, and Huai'an Kechuang Industrial Investment Co., Ltd. (LP) 1 million yuan, totaling 10 million yuan [1]